

Association of Helicobacter Pylori with Gall Stone Disease

Dr. Prince Jain¹, Dr. M. K. Maheshwari², Dr. Aditya Rastogi³ and Dr. Khushboo Sharma⁴

¹Junior Resident of Department of General Surgery Subharti Medical College, Meerut, Uttar Pradesh, India

²Professor & Head Department of General Surgery Subharti Medical College, Meerut, Uttar Pradesh, India

³Associate Professor department of general surgery, subharti medical college, meerut, Uttar Pradesh, India

⁴Junior Resident of Department of General Surgery Subharti Medical College, Meerut, Uttar Pradesh, India

*Corresponding Author
Dr. Prince Jain

Article History

Received: 08.08.2025

Revised: 15.09.2025

Accepted: 24.10.2025

Published: 02.11.2025

Abstract: **Background:** Gallstone disease (cholelithiasis) is a common gastrointestinal condition with multifactorial etiology, including genetic, metabolic, and microbial factors. *Helicobacter pylori* (*H. pylori*), a gram-negative bacterium linked to gastric pathologies, has been implicated in gallstone pathogenesis through mechanisms such as bile acid metabolism alterations, lipid profile changes, and chronic biliary inflammation. **Objectives:** This study evaluates the association between *H. pylori* infection and gallstone disease, examining demographic factors, clinical features, endoscopic findings, and histopathological outcomes. **Methods:** A prospective observational study was conducted on 100 patients diagnosed with gallstone disease. *H. pylori* detection employed Rapid Urease Test (RUT) and Giemsa staining. Clinical, demographic, endoscopic, and histopathological data were analyzed. **Results:** The cohort included 78% female participants, with a mean age of 41.91 ± 14.96 years and peak prevalence in the 20–39 age group (48%). Abdominal pain was the most frequent symptom (55%), followed by heartburn (30%) and bloating (15%). Endoscopy revealed antral gastritis in 73% and erosive gastritis in 27% of cases. Histopathology confirmed chronic cholecystitis with cholelithiasis in 89% and acute-on-chronic inflammation in 11%. *H. pylori* detection rates varied significantly between RUT (97%) and Giemsa staining (16%), with Giemsa positivity declining in older patients, highlighting diagnostic limitations. **Conclusions:** The findings suggest a potential link between *H. pylori* and gallstone disease, emphasizing the need for advanced molecular diagnostics. Further studies are warranted to elucidate *H. pylori*'s role in gallstone pathogenesis and explore its preventive potential.

Keywords: Gallstone disease, *Helicobacter pylori*, cholelithiasis, Rapid Urease Test, chronic cholecystitis.

INTRODUCTION

Gallstone disease (cholelithiasis) is a common gastrointestinal condition caused by the formation of stones in the gallbladder, which stores bile essential for digestion. These stones can lead to a spectrum of clinical manifestations, from asymptomatic cases to severe complications such as cholecystitis, pancreatitis, and biliary obstruction. The disease has a multifactorial etiology, involving genetic predisposition, metabolic abnormalities, and microbial factors.¹

Among potential microbial contributors, *Helicobacter pylori* (*H. pylori*), a gram-negative bacterium primarily associated with gastric pathologies, has garnered attention for its possible role in gallstone disease.² *H. pylori* is widely known for causing chronic gastritis, peptic ulcers, and gastric cancer, but its systemic effects—mediated through chronic inflammation, immune dysregulation, and metabolic changes—may extend to the biliary system.² Studies suggest that *H. pylori* may influence gallstone formation through mechanisms such as bile acid metabolism alterations, lipid profile changes, and chronic inflammation of the biliary epithelium.^{3–4}

Epidemiological data regarding the association between *H. pylori* and gallstone disease are conflicting.⁵ While some studies report a significant correlation,⁶ others find

no conclusive link,⁷ possibly due to differences in study design, population demographics, and geographical variations.⁵ Furthermore, the role of *H. pylori* in different gallstone types (cholesterol, pigment, and mixed stones) remains an area of active research, with hypotheses suggesting a stronger association with pigment stones due to bacterial involvement in bilirubin metabolism.⁸

Understanding the interplay between *H. pylori* and gallstone disease could have significant diagnostic and therapeutic implications.⁹ If a causal relationship is established, routine screening and eradication of *H. pylori* may serve as a preventive strategy for high-risk populations.⁵ This study aims to explore the potential association between *H. pylori* infection and gallstone disease, providing new insights into the microbial factors contributing to biliary pathology and addressing existing gaps in the literature.^{5–7}

MATERIAL & METHODS

This prospective observational study will be conducted in the Department of General Surgery at CSSH Medical College to investigate the clinical correlation between *Helicobacter pylori* infection and gallstone disease.

Study Duration

The research will be conducted over a two-year period, spanning from 2023 to 2025.

Ethical Considerations

Approval for the study will be obtained from the Institutional Ethics Committee prior to its commencement. All participants will provide written informed consent, ensuring voluntary participation and adherence to ethical research principles.

Sample Size and Population

The study will include 100 patients diagnosed with gallstone disease who meet the inclusion and exclusion criteria.

Inclusion Criteria

Patients with a clinical diagnosis of gallstone disease.

Individuals who voluntarily consent to participate in the study.

Exclusion Criteria

- Immunocompromised patients.
- Patients unwilling to participate.

METHODOLOGY

Gallbladder specimens will be collected from participants undergoing

cholecystectomy. Histopathological evaluation will be performed as follows:

Sections will be subjected to routine hematoxylin and eosin (H&E) staining for morphological analysis.

Additional sections will be processed using Giemsa staining to identify the presence of *H. pylori*.

Specimens will be fixed in 10% buffered formalin, and Giemsa staining will be performed using a modified protocol to enhance bacterial visualization. Light microscopy will be utilized to identify *H. pylori*-like bacteria, characterized as curved, spiral, bent, pole-like, or fusiform in morphology.

Statistical Analysis

Descriptive statistics will be used to summarize the data. Categorical variables will be compared using the Chi-square test, with a *p*-value of <0.05 considered statistically significant.

Informed Consent

All participants provided written informed consent after being informed of the study's objectives and procedures.

RESULT

The study enrolled 100 patients clinically diagnosed with gallstone disease, with a mean age of 41.91 ± 14.96 years. The majority of participants (48%) were between 20 and 39 years of age, followed by 34% in the 40–59 years group, 14% aged 60 years or above, and 4% under the age of 20. Female patients formed the predominant proportion of the study population, constituting 78%, while males accounted for 22%. These findings highlight the predominance of gallstone disease in younger to middle-aged individuals and its significant prevalence among females. (Table 1).

Table 1: Demographic Characteristics of Study Participants		
Characteristic	Subcategory	n(%)
Age Range (Years)	<20	4(4%)
	20–39	48(48%)
	40–59	34(34%)
	≥ 60	14(14%)
Mean Age	-	41.91 ± 14.96
Sex	Female	78(78%)
	Male	22(22%)

Abdominal pain emerged as the most frequently reported symptom, affecting 55% of the patients, making it the leading cause for seeking medical attention. This was followed by heartburn in 30% and abdominal bloating in 15%. The prominence of abdominal pain underscores its diagnostic relevance in gallstone disease. (Table 2).

Table 2: Clinical Presentation of Study Participants		
Chief Complaint	Number of Patients (n)	Percentage (%)
Pain Abdomen	55	55%
Heartburn	30	30%
Abdominal Bloating	15	15%

Diagnostic evaluation using upper gastrointestinal endoscopy revealed that antral gastritis was the most prevalent finding, observed in 73% of the patients, while 27% demonstrated erosive gastritis. Histopathological examination of gallbladder specimens further corroborated these findings, with 89% of patients diagnosed with chronic cholecystitis associated with cholelithiasis, and 11% diagnosed with acute cholecystitis with cholelithiasis. These findings emphasize the predominance of chronic inflammatory changes in the gallbladder among patients with gallstone disease. (Table 3).

Table3: Diagnostic Findings of Study Participants		
DiagnosticMethod	Finding	n(%)
UpperGIEndoscopy	AntralGastritis	73(73%)
	ErosiveGastritis	27(27%)
Histopathology	ChronicCholecystitiswithCholelithiasis	89(89%)
	AcuteCholecystitiswithCholelithiasis	11(11%)

The study explored the presence of *Helicobacter pylori* using two diagnostic modalities: the Rapid Urease Test (RUT) and Giemsa staining. The RUT demonstrated an overwhelming positivity rate of 97%, suggesting a high prevalence of *H. pylori* infection among the cohort. In contrast, Giemsa staining detected *H. pylori* in only 16% of the specimens, indicating potential methodological differences in sensitivity or variability in bacterial load. Age-stratified analysis revealed consistent positivity rates with RUT across all age groups, exceeding 94% in all categories. Conversely, Giemsa positivity declined with increasing age, being highest (25%) in patients under 20 years and absent in individuals aged 60 years or above. This divergence underscores the necessity to evaluate the diagnostic accuracy of different methodologies and their implications in assessing *H. pylori* infection. (Table 4).

Table4: Detection of H. pylori in Gall stone Patients		
DiagnosticTest	Result	n(%)
RapidUreaseTest(RUT)	Positive	97(97%)
	Negative	3(3%)
GiemsaStain	Positive	16(16%)
	Negative	84(84%)

These results suggest a significant association between *H. pylori* and gallstone disease, as evidenced by the high detection rates with RUT. The age-dependent decline in Giemsa positivity further reflects potential differences in bacterial distribution or host-pathogen interactions, warranting further investigation into the role of *H. pylori* in the pathogenesis of gallstone disease.

DISCUSSION

The present study investigated the association between *Helicobacter pylori* (*H. pylori*) infection and gallstone disease in a cohort of 100 patients, examining demographic factors, clinical features, endoscopic findings, and histopathological outcomes. The findings provide a nuanced perspective on the role of *H. pylori* in gallstone pathogenesis while emphasizing diagnostic challenges. The results are discussed in the context of previous literature to elucidate their implications.

The demographic analysis revealed a predominance of female participants (78%), consistent with prior studies reporting a higher prevalence of

gallstone disease in women due to hormonal factors, including estrogen-mediated cholesterol saturation in bile and progesterone-induced gallbladder hypomotility.¹⁻³ The mean age of 41.91 ± 14.96 years, with a peak prevalence in the 20–39 age group (48%), differs from findings in Western populations, where gallstone incidence typically peaks in the 40–60 age range.⁴ This younger age distribution aligns with regional variations in dietary habits, genetic predispositions, and infection patterns.⁵

Abdominal pain was the most commonly reported symptom (55%), consistent with the classical presentation of biliary colic described in numerous studies.⁵⁻⁶ The relatively high prevalence of heartburn

(30%) and bloating (15%) in this cohort is notable and suggests an overlap with functional dyspepsia, a condition often linked to *H. pylori* infection.⁷ Unlike Western populations, where gallstone disease often coexists with metabolic syndrome components such as obesity and diabetes,^{1–3} the absence of significant comorbidities in this study suggests a potentially different pathogenic mechanism in this population.

Endoscopic findings revealed a high prevalence of antral gastritis (73%) and erosive gastritis (27%), consistent with previous studies linking *H. pylori* infection to gastroduodenal inflammation.⁸ Histopathological analysis confirmed chronic cholecystitis with cholelithiasis in 89% of cases, closely aligning with classic descriptions of gallstone pathology.⁹ Acute-on-chronic inflammation was observed in 11% of cases, slightly lower than the 20–30% reported by previous studies,¹⁰ possibly reflecting earlier clinical interventions or differences in disease progression in this cohort. The detection of *H. pylori* revealed significant discrepancies between diagnostic methods, with a positivity rate of 97% using the Rapid Urease Test (RUT) and only 16% using Giemsa staining. Similar inconsistencies have been noted in earlier research, such as studies reporting higher detection rates of *H. pylori* DNA in gallbladder tissue using molecular techniques compared to traditional histological methods.¹¹ This highlights the limitations of conventional diagnostic tools in identifying *H. pylori* in extra-gastric sites and underscores the need for more sensitive molecular diagnostics, such as PCR or immunohistochemistry.

Age-specific trends in *H. pylori* positivity revealed that RUT maintained consistently high detection rates (>94%) across all age groups, while Giemsa staining positivity declined with age, reaching 0% in patients aged 60 years or older. This decline could be due to age-related changes in gallbladder mucosa, reducing bacterial colonization.¹² This finding contrasts with studies documenting increasing prevalence of gastric *H. pylori* infection with age,¹³ highlighting a possible divergence in the epidemiology of *H. pylori* in gastric and biliary environments.

This study adds to the growing body of evidence suggesting a potential link between *H. pylori* infection and gallstone disease, though the exact role remains contentious.¹⁴ While molecular studies have identified *H. pylori* DNA in gallbladder tissue, the inconsistencies in detection rates using different diagnostic methods underscore the need for further research. Future studies employing advanced molecular diagnostics and larger sample sizes are warranted to confirm the role of *H. pylori* in gallstone pathogenesis and determine whether it acts as a causative agent or a bystander in a multifactorial disease process.

CONCLUSION

This study highlights a significant association between *Helicobacter pylori* infection and gallstone disease, with a high detection rate of 97% via Rapid Urease Test (RUT). However, the low Giemsa stain positivity (16%) underscores diagnostic discrepancies, likely due to variations in test sensitivity, bacterial load, or potential false positives with RUT. Chronic cholecystitis with cholelithiasis predominated (89%), reflecting established gallstone-related pathology.

The demographic analysis revealed a marked female predominance (78%) and a declining Giemsa positivity with age, suggesting possible age-related changes in all bladder mucosal integrity or immuneresponse. While potential mechanisms, including bile composition alterations and gallbladder motility effects, support a role for *H. pylori* in gallstone pathogenesis, the findings also raise questions about whether this represents true biliary colonization or gastric contamination.

Standardized diagnostic protocols and advanced molecular techniques such as PCR are necessary for definitive *H. pylori* detection in biliary tissue. Further research is required to clarify the clinical relevance of *H. pylori* in gallstone disease, its pathogenic mechanisms, and the impact of eradication therapy, ensuring management remains aligned with established therapeutic practices.

REFERENCES

1. Stinton, S. M., and E. A. Shaffer. "Epidemiology of Gallbladder Disease: Cholelithiasis and Cancer." *Best Practice & Research Clinical Gastroenterology*, vol. 26, no. 6, 2012, pp. 1023–1032.
2. Randi, G., S. Franceschi, and C. L. Vecchia. "Gallbladder Cancer Worldwide: Geographical Distribution and Risk Factors." *International Journal of Cancer*, vol. 118, no. 7, 2006, pp. 1591–1602. <https://doi.org/10.1002/ijc.21683>.
3. Zhao, S., H. Zheng, X. Zhong, Z. Wang, Y. Su, and Y. Shi. "Effects and Mechanisms of *Helicobacter pylori* Infection on the Occurrence of Extra-Gastric Tumors." *World Journal of Gastroenterology*, vol. 30, no. 37, 2024, pp. 4090–4098. <https://doi.org/10.3748/wjg.v30.i37.4090>.
4. Suzuki, H., F. Franceschi, T. Nishizawa, and A. Gasbarrini. "Extragenic Manifestations of *Helicobacter pylori* Infection." *Helicobacter*, vol. 16, suppl. 1, 2011, pp. 65–69. <https://doi.org/10.1111/j.1523-5378.2011.00883.x>.
5. Kishor, K. M., S. Goel, and K. Varshney. "A Clinical Study on Correlation of *Helicobacter pylori* in Cholelithiasis." *International Journal of Scientific Research*, vol. 13, no. 3, 2024, pp. 276–282.

6. Jahantab, M., A. A. Safaripour, S. Hassanzadeh, and M. J. Y. Barhaghtalab. “Demographic, Chemical, and *Helicobacter pylori* Positivity Assessment in Gallstones.” *Canadian Journal of Gastroenterology and Hepatology*, 2021, Article ID 3351352. <https://doi.org/10.21275/mr241206174604>.
7. Bulajic, M., P. Maisonneuve, W. Schneider-Brachert, P. Müller, U. Reischl, C. Stain, et al. “*Helicobacter pylori* and Bile Stones: Association and Possible Role in Pathogenesis.” *Journal of Hepatology*, vol. 36, no. 1, 2002, pp. 113–118.
8. Boonyanugomol, W., C. Chomvarin, C. Hahnvajanawong, B. Sripa, M. Kaparakis-Liaskos, and R. L. Ferrero. “*Helicobacter pylori* Cag Pathogenicity Island (cagPAI) Involved in Bile Epithelial Inflammation.” *PLoS One*, vol. 8, no. 10, 2013, e77358. <https://doi.org/10.1371/journal.pone.0077358>.
9. Cen, L., J. Wu, S. Zhu, J. Pan, T. Zhou, T. Yan, et al. “The Potential Bidirectional Association between *Helicobacter pylori* Infection and Gallstone Disease in Adults: A Two-Cohort Study.” *European Journal of Clinical Investigation*, vol. 53, no. 2, 2023, e13879. <https://doi.org/10.1111/eci.13879>.
10. Shabanzadeh, D. M., L. T. Sørensen, and T. Jørgensen. “Gallstone Disease and Mortality: A Cohort Study.” *International Journal of Epidemiology*, vol. 45, no. 1, 2016, pp. 88–97.
11. Everhart, J. E., M. Khare, M. Hill, and K. R. Maurer. “Prevalence and Ethnic Differences in Gallbladder Disease in the United States.” *Gastroenterology*, vol. 117, no. 3, 1999, pp. 632–639.
12. Berger, M. Y., J. J. Van der Velden, J. G. Lijmer, H. de Kort, A. Prins, and P. J. Bindels. “Abdominal Symptoms: Do They Predict Gallstones? A Systematic Review.” *Scandinavian Journal of Gastroenterology*, vol. 35, no. 1, 2000, pp. 70–76.
13. Lamberts, M. P., A. L. Lagro-Janssen, L. J. Vleming, G. P. Westert, and M. E. Numans. “Symptoms and Syndromes Seen in General Practice: Chronic Abdominal Pain.” *Family Practice*, vol. 30, no. 1, 2013, pp. 1–7.
14. Talley, N. J., and A. C. Ford. “Functional Dyspepsia.” *New England Journal of Medicine*, vol. 381, no. 18, 2019, pp. 1741–1752.